Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Oncogene ; 22(9): 1400-10, 2003 Mar 06.
Artigo em Inglês | MEDLINE | ID: mdl-12618766

RESUMO

The mixed lineage leukemia gene (MLL, also known as HRX, ALL-1 and Htrx) located at 11q23 is involved in translocations with over 40 different chromosomal bands in a variety of leukemia subtypes. Here we report our analysis of a rare but recurring translocation, t(11;15)(q23;q14). This translocation has been described in a small subset of cases with both acute myeloblastic leukemia and ALL. Recent studies have shown that MLL is fused to AF15q14 in the t(11;15). Here we analyse a sample from another patient with this translocation and confirm the presence of an MLL-AF15q14 fusion. However, we have also identified and cloned another fusion transcript from the same patient sample. In this fusion transcript, MLL is fused to a novel gene, MLL partner containing FYVE domain (MPFYVE). Both MLL-AF15q14 and MLL-MPFYVE are in-frame fusion transcripts with the potential to code for novel fusion proteins. MPFYVE is also located on chromosome 15, approximately 170 kb telomeric to AF15q14. MPFYVE contains a highly conserved motif, the FYVE domain which, in other proteins, has been shown to bind to phosphotidyl-inositol-3 phosphate (PtdIns(3)P). The MLL-MPFYVE fusion may be functionally important in the leukemia process in at least some patients containing this translocation.


Assuntos
Cromossomos Humanos Par 11/genética , Cromossomos Humanos Par 15/genética , Leucemia Mieloide Aguda/genética , Proteínas de Fusão Oncogênica/genética , Proteínas/genética , Translocação Genética/genética , Motivos de Aminoácidos , Sequência de Aminoácidos , Sequência de Bases , Criança , Cromossomos Humanos Par 11/ultraestrutura , Cromossomos Humanos Par 15/ultraestrutura , DNA Complementar/genética , Etiquetas de Sequências Expressas , Humanos , Hibridização in Situ Fluorescente , Masculino , Dados de Sequência Molecular , Proteína de Leucina Linfoide-Mieloide , Proteínas Oncogênicas , Proteínas de Fusão Oncogênica/fisiologia , Estrutura Terciária de Proteína , Alinhamento de Sequência , Homologia de Sequência de Aminoácidos
2.
Int J Oncol ; 20(5): 977-82, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11956592

RESUMO

WNT signals are transduced to the JNK pathway, the Ca2+-releasing pathway, or the beta-catenin - TCF pathway through seven-transmembrane-type WNT receptors encoded by Frizzled genes (FZD1-FZD10). WRCH1/ARHV and CDC42 are potentially implicated in the WNT-JNK pathway. Here, WRCH2/ARHV cDNAs were isolated by using bioinformatics and cDNA-PCR. WRCH2 gene, consisting of at least 3 exons, encoded a 236-amino-acid protein with proline-rich domain and GTPase domain. WRCH2 was homologous to WRCH1 (55.4% total-amino-acid identity) and CDC42 (43.5% total-amino-acid identity). WRCH2 gene was located on human chromosome 15q15, which is one of fragile sites in the human genome. A single nucleotide substitution (632 Gright curved arrow A) was identified between WRCH2 cDNA and human genome draft sequences, which resulted in Arg177Lys amino-acid substitution. WRCH2 mRNA was relatively highly expressed in pancreas, placenta, and fetal brain. WRCH2 mRNA was over-expressed in TMK1 (gastric cancer), Hs700T (pancreatic cancer), HeLa S3 (cervical cancer), and A549 (lung cancer). WRCH2 mRNA was moderately expressed in MKN74, MKN45, MKN28, KATO-III (gastric cancer), HL-60 (pro-myelocytic leukemia), Raji (Burkitt's lymphoma), and SW480 (colorectal cancer). WRCH2 mRNA was up-regulated in 3 out of 8 cases of primary gastric cancer. Because Wrch1 can activate PAK1 and JNK1, and induce filopodium formation and stress fiber dissolution, over-expression of WRCH2 mRNA in human cancer cells might also lead to more malignant phenotype.


Assuntos
Cromossomos Humanos Par 15/ultraestrutura , Clonagem Molecular , Proteínas de Ligação ao GTP/biossíntese , Proteínas de Ligação ao GTP/genética , Mutação , Proteínas de Neoplasias/biossíntese , Proteínas de Neoplasias/genética , Proteínas rho de Ligação ao GTP , Sequência de Aminoácidos , Sequência de Bases , Northern Blotting , Cálcio/metabolismo , Mapeamento Cromossômico , DNA Complementar/metabolismo , Ativação Enzimática , Genoma Humano , Células HL-60 , Células HeLa , Humanos , Modelos Genéticos , Dados de Sequência Molecular , Fenótipo , Poli A/metabolismo , Reação em Cadeia da Polimerase , RNA Mensageiro/metabolismo , Distribuição Tecidual , Células Tumorais Cultivadas , Regulação para Cima
3.
Mol Diagn ; 4(3): 195-209, 1999 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10553020

RESUMO

BACKGROUND: The development of a rapid and simple reverse-transcription polymerase chain reaction (RT-PCR) assay is described that identifies the promyelocytic leukemia- retinoic acid receptor alpha (PML-RARa) hybrid messenger RNA (mRNA), a characteristic feature of acute promyelocytic leukemia (APL). METHODS AND RESULTS: Randomly primed complementary (cDNA) is synthesized from leukocyte RNA and amplified in the presence of Taq Gold in 2 separate reaction tubes containing primer pairs specific for intron 3 (bcr 3, long [L] form mRNA transcript) and intron 6 (bcr 1, short [S] form)/exon 6 (bcr 2, variant [V] form) breakpoints in PML, respectively. The different sized products generated from each RNA transcript (S, L, or V forms) are readily and unambiguously distinguishable after agarose gel electrophoresis without the need for either nested PCR or hybridization. The sensitivity of the assay is 1 in 10,000 to 1 in 100,000. The separate amplification of a b2-microglobulin transcript controls for adequate RNA and cDNA preparation. The newly developed assay was used clinically for the evaluation of 78 patients with APL. It was rapid and more sensitive than cytogenetic karyotyping, both for the diagnosis of APL and the assessment of minimal residual disease (MRD) after therapy. RT-PCR detected PML-RARa mRNA in all cases positive for the t(15;17) translocation by cytogenetics. However, as many as 50% and 80% of the diagnostic specimens and the specimens for MRD assessment, respectively, that were positive by RT-PCR were negative by cytogenetics. The ratio of cases with L-form to S-form PML-RARa fusion transcript was 2:1, whereas 3 cases (10%) had fusion sites in exon 6 of the PML gene (V forms). In addition, approximately 50% of the patients were diagnosed morphologically with microgranular M3V-type leukemia, but no significant correlation with PML breakpoints was found. CONCLUSION: The current assay is rapid, sensitive, and specific without using nested PCR or hybridization.


Assuntos
Biomarcadores Tumorais/genética , Cromossomos Humanos Par 15/ultraestrutura , Cromossomos Humanos Par 17/ultraestrutura , Hibridização in Situ Fluorescente , Cariotipagem , Leucemia Promielocítica Aguda/genética , Proteínas de Neoplasias/genética , Proteínas de Fusão Oncogênica/genética , RNA Mensageiro/análise , RNA Neoplásico/análise , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Translocação Genética , Exame de Medula Óssea , Cromossomos Humanos Par 15/genética , Cromossomos Humanos Par 17/genética , Éxons/genética , Feminino , Humanos , Leucemia Promielocítica Aguda/diagnóstico , Leucemia Promielocítica Aguda/patologia , Masculino , Vírus da Leucemia Murina de Moloney/enzimologia , Neoplasia Residual , Células Neoplásicas Circulantes , DNA Polimerase Dirigida por RNA/metabolismo , Proteínas dos Retroviridae/metabolismo , Sensibilidade e Especificidade , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA